{"id":223,"date":"2020-12-08T22:14:48","date_gmt":"2020-12-09T03:14:48","guid":{"rendered":"https:\/\/www.cd-bioparticles.com\/blog\/?p=223"},"modified":"2020-12-08T22:14:48","modified_gmt":"2020-12-09T03:14:48","slug":"a-nanobody-can-neutralize-sars-cov-2-by-stabilizing-inactive-spike-protein","status":"publish","type":"post","link":"https:\/\/www.cd-bioparticles.com\/blog\/magnetic-beads\/a-nanobody-can-neutralize-sars-cov-2-by-stabilizing-inactive-spike-protein\/","title":{"rendered":"A Nanobody Can Neutralize SARS-CoV-2 by Stabilizing Inactive Spike Protein"},"content":{"rendered":"\n<div class=\"wp-block-image\"><figure class=\"aligncenter\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"\/blog\/wp-content\/uploads\/2020\/12\/A-Nanobody-Can-Neutralize-SARS-CoV-2-by-Stabilizing-Inactive-Spike-Protein-1-1024x576.jpg\" alt=\"\" class=\"wp-image-224\" srcset=\"\/blog\/wp-content\/uploads\/2020\/12\/A-Nanobody-Can-Neutralize-SARS-CoV-2-by-Stabilizing-Inactive-Spike-Protein-1-1024x576.jpg 1024w, \/blog\/wp-content\/uploads\/2020\/12\/A-Nanobody-Can-Neutralize-SARS-CoV-2-by-Stabilizing-Inactive-Spike-Protein-1-300x169.jpg 300w, \/blog\/wp-content\/uploads\/2020\/12\/A-Nanobody-Can-Neutralize-SARS-CoV-2-by-Stabilizing-Inactive-Spike-Protein-1-768x432.jpg 768w, \/blog\/wp-content\/uploads\/2020\/12\/A-Nanobody-Can-Neutralize-SARS-CoV-2-by-Stabilizing-Inactive-Spike-Protein-1.jpg 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div>\n\n\n\n<p>In the past 20 years, there are three zoonotic\n\u03b2-coronaviruses that have entered the human population and caused severe\nrespiratory symptoms with high mortality. Caused by SARS-CoV-2, the COVID-19\npandemic is the easiest to spread among the three coronaviruses. So far, no\npreventive treatment for the coronavirus has been approved, and the timetable\nfor the effective and widely available vaccine against SARS-CoV-2 is still\nuncertain. Therefore, the development of new treatment and prevention methods\nremains crucial. <\/p>\n\n\n\n<p>In a new study, researchers from the University of\nCalifornia, San Francisco and other research institutions screened yeast\nsurface display libraries (containing more than 2\u00d710<sup>9<\/sup> synthetic\nnanobody sequences) that bind to the S protein extracellular domain\n(ectodomain), and they isolated single domain antibody (Nanobody) that\nneutralizes SARS-CoV-2. Their relevant research results were recently published\nin the journal <em>Science<\/em>,\nwith the title of the paper <em>An ultrapotent synthetic nanobody neutralizes\nSARS-CoV-2 by stabilizing inactive Spike.<\/em><\/p>\n\n\n\n<p>The virus particles of the coronavirus are surrounded by a\nmembrane containing the homotrimeric transmembrane glycoprotein, the spike\nprotein (S protein), which is responsible for the virus to enter the host cell.\nThe surface exposed part of S protein consists of two domains, S1 and S2. S1\nbinds to the host cell receptor angiotensin converting enzyme 2 (ACE2), while\nS2 catalyzes the fusion of the virus and the host cell membrane.<\/p>\n\n\n\n<p>These authors used a mutant form of SARS-CoV-2 S protein\n(SpikeS2P) as an antigen, and labeled SpikeS2P with biotin or with fluorescent\ndyes, and through multiple rounds of screening&#8212;first through magnetic bead\nbinding followed by fluorescence-activated cell sorting&#8212;to select yeasts\ndisplaying nanobodies. These nanobodies are divided into two categories, namely\nClass I and Class II nanobodies.<\/p>\n\n\n\n<p>In the study, Class II neutralizing nanobodies potentially\nshow a new mechanism to disrupt the function of S protein. The paired use of\nclass I and class II nanobodies in a preventive or therapeutic cocktail could\nstrongly neutralize and prevent the escape variant of SARS-CoV-2. Therefore,\nthe combined stability, effectiveness, and diverse epitope binding of the\nanti-S protein nanobodies screened by these authors provide a unique potential\nprevention and treatment strategy for limiting the continued deaths caused by\nthe COVID-19 pandemic.<\/p>\n\n\n\n<p><strong>About the author<\/strong> <\/p>\n\n\n\n<p>CD Bioparticles is a leading manufacturer of magnetic particles and related products for immunoassay development. It provides a comprehensive list of immunomagnetic bead products conjugated with different coating materials and functional groups in multiple sizes to meet needs for research and industrial prospect development. It has recently developed a series of <a href=\"https:\/\/www.cd-bioparticles.com\/product\/antibody-list-135.html\">SARS-CoV-2 magnetic particles<\/a> for research applications in immunoprecipitation and minimum protein purification to support the entire scientific community in their efforts to fight against SARS-CoV-2 and COVID-19.  <\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>Reference<br>Schoof, M., Faust, B., Saunders, R. A., Sangwan, S., Rezelj, V., Hoppe, N., &#8230; &amp; Kratochvil, H. T. (2020). An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. <\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>In the past 20 years, there are three zoonotic \u03b2-coronaviruses that have entered the human population and caused severe respiratory<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,6],"tags":[4,59,60],"class_list":["post-223","post","type-post","status-publish","format-standard","hentry","category-applications","category-magnetic-beads","tag-magnetic-particles","tag-sars-cov-2","tag-sars-cov-2-magnetic-particles"],"_links":{"self":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts\/223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/comments?post=223"}],"version-history":[{"count":1,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts\/223\/revisions"}],"predecessor-version":[{"id":225,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/posts\/223\/revisions\/225"}],"wp:attachment":[{"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/media?parent=223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/categories?post=223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cd-bioparticles.com\/blog\/wp-json\/wp\/v2\/tags?post=223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}